CLINICAL_TRIALS
trial_result
· 2021-10-21
Clinical Trial Update: Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment [Phase 2, Phase 3]
Summary
Phase 2/3 trial update on BRM421 for dry eye syndrome, reporting completed results as of 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: BRIM Biotechnology Inc. | Conditions: Dry Eye Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-10-21